Lack of association between MTHFR C677T polymorphism and breast cancer risk in Ahvaz, west south‑Iran

Association between C677T polymorphism of the methylenetetrahydrofolate reductase (MTHFR), a key enzyme involved in folate metabolism and DNA methylation, and breast cancer risk are inconsistent. We investigated in a case‑control study, possible effect of the common MTHFR C677T polymorphism on breast cancer risk in a sample of Iranian patients.

The study subjects comprised of 123 breast cancer cases and 110 cancer‑free control, who were matched for age and body mass index (BMI). C677T genotypes were determined by polymerase chain reaction‑restriction fragment length polymorphism (PCR‑RFLP) assay. Lipid profile was measured in all subjects by standard method.

The genotypes distributions (CC, CT, and TT) were 55.3, 39, and 5.7% in breast cancer cases and 51.8, 44.5, and 3.6% in controls. Chisquare analysis revealed that there was no significant association between breast cancer risk and MTHFR genotypes and alleles. Additionally, no significant association was observed between C677T genotypes and biochemistry parameters. Amultinomial logistic regression model with MTHFR genotypes, lipid profiles, BMI and age as covariates revealed that there is no significant association between MTHFR genotypes and risk of breast cancer, but higher values of LDL and HDL significantly increase risk of breast cancer.

Our findings do not support the hypothesis that genetic variation in the MTHFR C677T polymorphism is implicated in the breast cancer risk in a sample of Iranian patients.